The Virology/Pharmacology Core Laboratory (VPCL) will represent an integral component of the Atlanta/Emory CFAR. While individual members of the Atlanta/Emory AIDS research community have strong records of collaborative AIDS research and scientific accomplishment, state-of-the- art virology and pharmacology resources are not generally available. We propose to provide essential virology and pharmacology support to all Atlanta/Emory CFAR investigators. We propose to make the services of this laboratory available to all Atlanta/Emory CFAR basic and clinical research scientists, and to provide them with technical support as they conduct virologic and pharmacologic studies in humans and non-human primates.
Specific Aims are: 1) to provide comprehensive quantitative, genotypic and phenotypic analyses of virus populations present in HIV-infected individuals participating in studies of the natural history and pathogenesis of HIV infection and in clinical trials, and to participate in national QC/QA testing to ensure standardization and validity of all analytical methods used. Analogous virologic techniques have also been developed to study SIV infection in non-human primates and these will be provided by the VPCL; 2) to perform state of the art pharmacologic assays to facilitate studies of the pharmacokinetics, pharmacodynamics, and metabolism of novel anti-retroviral drugs, and of patient adherence to complex medical regimens; 3) to provide training in proper virologic and pharmacologic methods to junior HIV researchers and investigators new to HIV research. Emphasis will be on teaching the safe handing of infectious materials, proper methods to cultivate cells and virus isolates, phenotypic and genotypic methods to characterize HIV, and the laboratory assessment of anti-retroviral drug susceptibility, drug composition and drug metabolism; and 4) to provide the necessary scientific leadership to assist Atlanta-Emory CFAR investigators as they develop novel approaches for the study of HIV pathogenesis and treatment. We will emphasize newly developed virological and analytical assays, and strive to nurture collaborative interactions under the umbrella of the Atlanta-Emory CFAR.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Center Core Grants (P30)
Project #
1P30DA012121-01
Application #
6104209
Study Section
Project Start
1998-08-01
Project End
1999-07-31
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
1
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Emory University
Department
Type
DUNS #
042250712
City
Atlanta
State
GA
Country
United States
Zip Code
30322
Hulgan, Todd; Stein, James H; Cotter, Bruno R et al. (2013) Mitochondrial DNA variation and changes in adiponectin and endothelial function in HIV-infected adults after antiretroviral therapy initiation. AIDS Res Hum Retroviruses 29:1293-9
Huang, Jeannie S; Hughes, Michael D; Riddler, Sharon A et al. (2013) Bone mineral density effects of randomized regimen and nucleoside reverse transcriptase inhibitor selection from ACTG A5142. HIV Clin Trials 14:224-34
Haubrich, Richard H; Riddler, Sharon A; Ribaudo, Heather et al. (2011) Initial viral decay to assess the relative antiretroviral potency of protease inhibitor-sparing, nonnucleoside reverse transcriptase inhibitor-sparing, and nucleoside reverse transcriptase inhibitor-sparing regimens for first-line therapy of HIV infection AIDS 25:2269-78
Hulgan, Todd; Haubrich, Richard; Riddler, Sharon A et al. (2011) European mitochondrial DNA haplogroups and metabolic changes during antiretroviral therapy in AIDS Clinical Trials Group Study A5142. AIDS 25:37-47
Thomas, Ajit G; Bodner, Amos; Ghadge, Ghanashyam et al. (2009) GCP II inhibition rescues neurons from gp120IIIB-induced neurotoxicity. J Neurovirol 15:449-57
Haubrich, Richard H; Riddler, Sharon A; DiRienzo, A Gregory et al. (2009) Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. AIDS 23:1109-18
Pillai, Vinod Bhaskara; Hellerstein, Michael; Yu, Tianwei et al. (2008) Comparative studies on in vitro expression and in vivo immunogenicity of supercoiled and open circular forms of plasmid DNA vaccines. Vaccine 26:1136-41
Riddler, Sharon A; Haubrich, Richard; DiRienzo, A Gregory et al. (2008) Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 358:2095-106
Sadagopal, Shanmugalakshmi; Amara, Rama Rao; Kannanganat, Sunil et al. (2008) Expansion and exhaustion of T-cell responses during mutational escape from long-term viral control in two DNA/modified vaccinia virus Ankara-vaccinated and simian-human immunodeficiency virus SHIV-89.6P-challenged macaques. J Virol 82:4149-53
Lai, Lilin; Vodros, Dalma; Kozlowski, Pamela A et al. (2007) GM-CSF DNA: an adjuvant for higher avidity IgG, rectal IgA, and increased protection against the acute phase of a SHIV-89.6P challenge by a DNA/MVA immunodeficiency virus vaccine. Virology 369:153-67

Showing the most recent 10 out of 42 publications